Download Referenser Diabetes

Referenser Diabetes
Nationella dokument
●
SBU, utvärdering – mat vid diabetes, 2010.
●
Socialstyrelsens Nationella riktlinjer för diabetesvården 2010. www.socialstyrelsen.se/nationellariktlinjerfordiabetesvarden
●
Egna mätningar av blodglukos vid diabetes utan insulinbehandling. SBU rapport 2009.
●
Nationella diabetesregistret (NDR) 2008.
●
Läkemedelsverket: Läkemedelsbehandling vid typ 2-diabetes – ny behandlingsrekommendation 2010.
Prevalens – Incidens
●
●
Diabetes - a global threat Lancet 2009;373:1735.
Berger B et al. Incidence, prevalence, and mortality of diabetes in a large population Diabetes
Care1999;22:773.
●
Andersson DKG et al. Prevalence and incidence of diabetes in a Swedish community 1972-1987 Diabet
Med 1993;10:606-13.
HbA1c
●
Bjellerup P, Nordin G, Jeppsson JO. Genomförande av IFCC-kalibreringen för HbA1c – rekommendationer från SFKK och EQUALIS. DiabetologNytt 2010;23:95-99
●
Bäck SE et al. An attempt at harmonization between three hospital laboratories in Skåne, Sweden. Clin
Chem Lab Med 1999;37:573-92
Klassifikation – behandlingsgrunder
●
Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexedDiabetologia 2005;48;2195-9.
●
Gastaldelli A et al. Beta-cell dysfunction and glucose intolerance: results from the San Antoniometabolism (SAM) study Diabetologia 2004;47:31-39.
●
Karlsson E et al. MODY - en autosomalt dominant form av diabetes. Diagnos via gentestning ger bättre
behandling Läkartidningen 2007;104:2600.
●
Diabetes—a global threat Lancet 2009;373:1735.
Fysisk aktivitet
●
●
FYSS 2008
Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with
impaired glucose tolerance. New Engl J Med 2001;344:1343-50.
●
Ramachandran A et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and
metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
Diabetologia 2006;49:289-97.
●
Diabetic prevention program research group. Reduction in the incidence of type 2 diabetes with life style
intervention or metformin New Engl J Med 2002;346:393-403.
●
Boulé NG et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a metaanalysis of controlled clinical trials. JAMA 2001;286:1218-2714.
●
Hansen D et al. Continuous low- to moderate-intensity exercise training is as effective as moderate- to
high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients. Diabetologia
2009;52:1789-97.
●
Cederholm J et al. Samband mellan risk-faktorer och komplikationer vid diabetes. Rapport efter 13 år
med Nationella diabetesregistret (NDR). Läkartidningen 2009;106:2684.
BAKGRUNDSMATERIAL SKÅNELISTAN 2011
1 (3)
2 (3)
Multifaktoriell behandling – blodsocker, lipider, blodtryck
●
The diabetes control and complication trial research group. The effect of intensive treatment of diabetes
on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
New Engl J Med 1993;329:977-86.
●
UK prospective diabetic study (UKPDS) group. Intensive blood glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
Lancet 1998;352:837-53.
●
Stratton M et al. Association of glycaemia with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:1405-12.
●
Holman RR et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. New Engl J
med 2008;359:1565-76.
●
UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin
on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-65.
●
Gaede P et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New
Engl J Med 2003;348:383-93.
●
Gaede P et al. Effect of Multifactorial Intervention on Mortality in Type 2 Diabetes. New Engl J Med 2008.
358:580-91.
Riktvärden för behandlingsmål
●
The ACCORD Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New Engl J Med
2008. 358:2545-59.
●
The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients
with Type 2 Diabetes. N Engl J Med 2008;358:2560-72.
●
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD,
ADVANCE, and VA Diabetes Trials. DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009
Hypoglykemi
●
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.
Diabetologia 2002;45:937-48.
●
Bartley PC et al. Long-term efficacy and safety of insulin determir compared to neutral protamine hagedorn insulin in patients with type 1 diabetes using a treat to target basal-bolus regimen with insulin aspart
at meals: a 2-year randomized, controlled trial. Diabetic Medicine 2008;25:442-49.
●
Rosenstock J et al. A randomized 52-week, treat to target trial comparing insulin detemir with insulin
glargine when asministrated as add-on to glucose-lowering drugs in insulin naïve people with type 2 diabetes. Diabetologia 2008;51:408-16.
●
●
Fors P. Dagens målvärden vid diabetes inte självklara för äldre-äldre. Läkartidningen 2009;106:1639
Östgren CJ et al. Fördel minska diabetsbehandlingen hos svårt multisjuka med lågt HBa1c. Läkartidningen 2009;106:1649.
Behandlingsstrategi vid typ 2 diabetes
●
UK prospective diabetes study (UKPDS) group. Intensive blood glucose control with sulphonylureas or
insulin compared with cxonventionel treatment and risk of complications in patient with type 2 diabetes.
Lancet 1998;352:837-53.
●
Nathan DM et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algoritm for the
initiation and adjustment of therapy. Diabetes Care 2009;32;193-203.
●
Kahn SE et al. Glycemic durability of rosiglitazone, metformin and glyburide monotherapy. New Engl J
Med 2006;355:2427-43.
●
National Institute for Health and clinical excellence.nType 2 diabetes – newer agents. Jun 2009. http://
guidance.nice.org.uk/CG87.
BAKGRUNDSMATERIAL SKÅNELISTAN 2011
3 (3)
SU
●
Bolen S et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2
diabetes. Ann Int Med 2007;147:sept.
●
Kahn SE et al. Glycemic durability of rosiglitazone, metformin or glyburide monitherapy. New Engl J Med
2006;355:2427-43
●
David M et al. Medical Management of Hyperglycemia inType 2 Diabetes: A Consensus Algorithm for the
Initiation and Adjustment of Therapy-A consensus statement of the American Diabetes Association and
the European Association for the Study of Diabetes Diabetes Care 2008. Volume 31, Number 12.
Tiazolidindioner
●
Yki-Järvinen H. Thiazolidindiones. New Engl J Med 2004;51:1106-18.
●
Singh S et al. Long-term risk of cardiovascular events with rosiglitazone. JAMA 2007;298;1189- 95
●
Douglas IJ et al. The risk of fractures associated with thiazolidinediones: a self controlled case-series
study. PLoS 2009;6.
●
Grey A. Skeletal consequences of thiazolidinedions therapy. Osteoporosis Int 2008. 19:129-37.
●
Fong DS and Contreras R. Glitazone use associated with diabetic macular oedema. Am J Ophtal-mol
2009. 147;583-6.
Insulin
●
Heise T et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin
glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
●
Lasserson DS et al. Optimal insulin regimens in type 2 diabetes mellitus: systermatic review and metaanalysis. Diabetologia 2009;52:1990-2000.
●
British National Institute of Clinical Excellence, NICE. The clinical effectiveness of long acting insulin
analogues for diabetes. www.nice.org.uk
●
Rosenstock J et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine
Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Diabetologia 2009;52:1778-88.
●
Rosenstock J et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH)
insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia
2009;52:1971-3.
●
Bartley P C et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Medicine 2008; 25:442–49.
Diabetes och äldre
●
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff
DC jr, Bigger JT, Buse JT et al. Effects of intensive glucose lowering in type 2 diabetes. J Engl J Med
2008;358:2545-59.
●
Lindström T, Jorfeldt L, Tegler L, Arnqvist HJ. Hypoglycaecemi and cardiac arrytmies in patient with type
2 diabetes mellitus.‘Diab Med 1990 1990;9: 536-41.
Hjälpmedel för insulinbehandling
●
Agardh CD, Berne C, Östman J. Diabetes. Stockholm: Liber; 2005.
●
http://www.diabeteshandboken.se
BAKGRUNDSMATERIAL SKÅNELISTAN 2011